Arsenic trioxide in front-line therapy of acute promyelocytic leukemia (C9710): prognostic significance of FLT3 mutations and complex karyotype

Xavier PoiréSection of Hematology/Oncology, The University of Chicago Medical Center, Chicago, IL, USA

Barry K. MoserDuke Translational Medicine Institute, Durham, NC, USA

Robert E. GallagherMontefiore Medical Center, Bronx, NY, USA

Kristina LaumannMayo Clinic, Rochester, MN, USA

Clara D. BloomfieldThe Ohio State University Comprensive Cancer Center, Columbus, OH, USA

Bayard L. PowellWake Forest Baptist Medical Center, Winston-Salem, NC, USA

Gregory KovalSection of Hematology/Oncology, The University of Chicago Medical Center, Chicago, IL, USA

Kabir GulatiSection of Hematology/Oncology, The University of Chicago Medical Center, Chicago, IL, USA

Nicholas HolowkaSection of Hematology/Oncology, The University of Chicago Medical Center, Chicago, IL, USA

Richard A. LarsonSection of Hematology/Oncology, The University of Chicago Medical Center, Chicago, IL, USA

Martin S. TallmanDivision of Hematology-Oncology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA

Frederick R. AppelbaumFred Hutchinson Cancer Research Center, Seattle, WA, USA

Dorie SherSection of Hematology/Oncology, The University of Chicago Medical Center, Chicago, IL, USA

Cheryl WillmanUniversity of New Mexico School of Medicine, Albuquerque, NM, USA

Elisabeth PaiettaMontefiore Medical Center, Bronx, NY, USA

Wendy StockSection of Hematology/Oncology, The University of Chicago Medical Center, Chicago, IL, USACorrespondence[email protected]

Your download is now in progress and you may close this window